Pablo L Ortiz-Romero

Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG

Iris Amitay‐Laish, Keila Mitsunaga, Pablo L Ortiz-Romero, Adèle de Masson et autres

Janus kinase inhibitors (JAKis) are increasingly used in patients with mycosis fungoides (MF)/Sézary syndrome (SS), often outside of intentional lymphoma-directed treatment, yet their real-world impact remains uncertain and poorly characterized. Our multicentre experience suggests that disease acceleration may occur in specific clinical …

il (code pays fourni par la source)

European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders

Rein Willemze, Chalid Assaf, Martine. Bagot, Marie Beylot-Barry et autres

In recent classifications several cutaneous lymphomas were reclassified as lymphoproliferative disorder (LPDs). These include primary cutaneous CD4+ small/medium T-cell LPD (PCSM-TCLPD), primary cutaneous acral CD8+ T-cell LPD (acral CD8+ TCLPD) and primary cutaneous marginal zone lymphoma/LPD (PCMZL/LPD). The latter is still classified …